In re Nexium (Esomeprazole) Antitrust Litigation, No. 1:12-md-02409-WGY (D. Mass.)

In Nexium, Faruqi & Faruqi, who filed the very first complaint on behalf of direct purchasers, represents a certified class of direct purchasers of the prescription drug Nexium.  The direct purchaser class alleges that in the brand manufacturer, AstraZeneca, entered into illegal reverse-payment agreements with certain generic manufacturers (namely Ranbaxy, Teva, and Dr. Reddy’s) to delay the entry of more affordable generic Nexium.  The class also alleges that AstraZeneca brokered a single conspiracy among all 3 generic manufacturers to achieve that same illegal delay in generic competition.  The case has proceeded through dispositive motions practice and is scheduled for trial in October of 2014.  Peter Kohn is on the trial team for this case.